SEATTLE, Oct. 9, 2012 (GLOBE NEWSWIRE) -- Immune Design today announced that the United States Patent and Trademark Office (USPTO) has granted two patents covering both of the Company’s principal technologies; GLA, a synthetic vaccine adjuvant, and ID-LV, a novel vector engineered to selectively target human dendritic cells and enhance the potency and duration of the induced cellular immune response.
